{"prompt": "['5 STUDY ENROLLMENT AND WITHDRAWAL', '5.1', 'Patient Inclusion Criteria', 'Each patient must meet all of the following criteria to be enrolled in this study:', '1. Is capable of understanding the written informed consent, provides signed and', 'witnessed written informed consent, and agrees to comply with protocol', 'requirements.', '2. Is between the ages of 18 and 75 years, inclusive, at the start of screening (both', 'male and female patients are to be included).', '3. Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition', '(DSM-5) criteria for Bipolar I or Bipolar Il Disorder as confirmed by the', 'investigator or sponsor-approved expert site-based rater by a M.I.N.I.', 'International Neuropsychiatric Interview and meeting all of the following 5 criteria:', 'a. The start of the current MDE is at least 2 weeks but no more than', '6 months prior to the screening visit;', 'b. Appropriate severity of illness, at least moderately ill, as measured by a', 'rater-administered MADRS total score >20 and corresponding to a CGI-', 'BP-S score of >4 at the screening and baseline visits;', 'C. Sufficient history and/or independent report (such as family member or', 'outside practitioner) verifying that the current MDE is causing clinically', 'significant distress or impairment in social, occupational, or other', 'important areas of functioning;', 'd. A lifetime history of at least 1 Bipolar manic episode or mixed episode', '(for Bipolar I) or hypomanic episode (for Bipolar II);', 'e. A rater-administered YMRS total score of 12 at the screening and', 'baseline visits.', '4. Has a body mass index (BMI) of 19 - 35 kg/m\u00b2, inclusive.', '5. Either must agree to use highly effective methods of birth control (defined as', 'those, alone or in combination, that result in a failure rate less than 1 percent per', 'year when used consistently and correctly) for at least 2 weeks prior to', 'randomization (starting with signing informed consent) through to the end-of-', 'study follow-up visit or must be of non-childbearing potential (defined as either', 'permanently sterilized or, if female, post-menopausal; the latter is defined as at', 'least 1 year with no menses without an alternative medical explanation).', 'Intra-Cellular Therapies, Inc. Confidential', '12 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['6. In the opinion of the investigator, the patient is willing and able to comply with', 'study requirements, study visits, and to return to the clinic for follow-up', 'evaluations as specified by the protocol.', '5.2', 'Patient Exclusion Criteria', 'Patients meeting any of the following criteria will be excluded from the study:', '1. The patient experiences a decrease in the rater-administered MADRS total score', 'of >25% between screening and baseline visits.', '2. In the opinion of the investigator, the patient has a significant risk for suicidal', 'behavior during the course of his or her participation in the study or', 'a. At screening, the patient scores \"yes\" on Items 4 or 5 in the Suicidal', 'Ideation section of the C-SSRS with reference to a 6-month period prior to', 'screening; or', 'b. At screening, the patient has had 1 or more suicidal attempts with', 'reference to a 2-year period prior to screening; or', 'C. At the baseline visit, the patient scores \"yes\" on Items 4 or 5 in the', 'Suicidal Ideation section of the C-SSRS with reference to screening; or', 'd. At screening or the baseline visit, scores >4 on Item 10 (suicidal thoughts)', 'on the rater-administered MADRS; or', 'e. Considered to be an imminent danger to himself, herself, or others.', '3. The patient is pregnant or breast-feeding; female patients of childbearing potential', 'must have negative urine and serum pregnancy tests at screening and a', 'negative urine pregnancy test on Day 1 prior to study treatment administration.', '4. The patient has a history within 12 months of screening, based on previous', 'psychiatric evaluation or a confirmed diagnosis upon screening based on the', 'DSM-5, of a psychiatric diagnosis other than Bipolar Disorder, including:', 'a. Schizophrenia or other psychotic disorder;', 'b. Anxiety disorders such as panic disorder, general anxiety disorder, or', 'post-traumatic stress disorder as a primary diagnosis (however, anxiety', 'symptoms may be allowed, if secondary to Bipolar Disorder, provided', 'these symptoms do not require current treatment);', 'C. Feeding or eating disorder;', 'd. Primary diagnosis of obsessive compulsive disorder;', 'e. Personality disorder;', 'Intra-Cellular Therapies, Inc. Confidential', '13 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}